take take puls pipelin
top bottom-lin beat print look
futur pipelin growth come next year
replac current base busi soon like greater
competit gener biosimilar investor remain
focus extern deal might build pipelin
quarter reflect potenti opportun could surpris
upsid think potenti near-term opportun
aimovig migrain mutein oncolog bite
factor revenu aimovig current though could get proof
concept earlier program oncolog immunolog next
month look expect rest model top revenu
close high end guidanc earn
high end guidanc
street underestim migrain blockbust
opportun assum signific ramp
found notabl referenc potenti bolu patient
quarter call prior call note differ compar
sinc clear outcom data emerg treatment
migrain compar estim sale
month sale sale think robust
migrain launch would surpris certainli risk neutral thesi
risk neutral rate target price includ greater
expect commerci competit key product enbrel neulasta
rais ep due better expect earn due
lower opex greater resili base busi product vs prior
forecast ep vs previous
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani engag
develop manufactur wide rang therapeut
unit state intern
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
scenario associ peak sale
repatha tri repres would
happen abl block regeneron/sanofi praulent
market
grey scenario associ peak sale
repatha tri repres would
happen outcom result under-perform expect term
abil acceler script write payer approv
 close
craze oncolog pay attent immunolog
novel target could conveni dose took time
call program run three studi lupu ra
chronic graft vs host diseas note nektar program partner
lilli similar think modul t-reg minim effect
effector nk cell could power mechan watch
program close next month
tri figur whether intern bite take share
oncolog whether need take bite extern acquisit
oncolog think bite antibodi approach could attract rel
car-t sinc off-the-shelf howev think significantli behind
program vs competitor note call could
inform later year bite hle-bit
understand whether bite could gener data similar efficaci bmca car-t
construct overal import question industri cours put
bmca game quickli speak compani post call
also highlight use bite technolog differ
antibodi drug conjug approach program short long-act
relat thesi remain cautiou see pipelin
opportun either extern intern play sinc still see
threat base busi also expect convers pick
ip biosimilar debat includ sandoz case mid-
june start two potenti neulasta biosimilar coheru
risk sensipar gener later year
compani mention price
